- Home
- GIGM vs BIVI Comparison
GIGM vs BIVI Comparison
Compare GIGM & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- BIVI
- Stock Information
- Founded
- GIGM 1998
- BIVI 2013
- Country
- GIGM Taiwan
- BIVI United States
- Employees
- GIGM N/A
- BIVI N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- BIVI Health Care
- Exchange
- GIGM Nasdaq
- BIVI Nasdaq
- Market Cap
- GIGM 16.1M
- BIVI 15.0M
- IPO Year
- GIGM 2000
- BIVI N/A
- Fundamental
- Price
- GIGM $1.55
- BIVI $1.61
- Analyst Decision
- GIGM
- BIVI
- Analyst Count
- GIGM 0
- BIVI 0
- Target Price
- GIGM N/A
- BIVI N/A
- AVG Volume (30 Days)
- GIGM 10.4K
- BIVI 497.0K
- Earning Date
- GIGM 10-29-2025
- BIVI 08-15-2025
- Dividend Yield
- GIGM N/A
- BIVI N/A
- EPS Growth
- GIGM N/A
- BIVI N/A
- EPS
- GIGM N/A
- BIVI N/A
- Revenue
- GIGM $3,250,000.00
- BIVI N/A
- Revenue This Year
- GIGM N/A
- BIVI N/A
- Revenue Next Year
- GIGM N/A
- BIVI N/A
- P/E Ratio
- GIGM N/A
- BIVI N/A
- Revenue Growth
- GIGM N/A
- BIVI N/A
- 52 Week Low
- GIGM $1.30
- BIVI $1.42
- 52 Week High
- GIGM $1.80
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- GIGM 53.16
- BIVI 25.00
- Support Level
- GIGM $1.45
- BIVI $1.42
- Resistance Level
- GIGM $1.65
- BIVI $1.65
- Average True Range (ATR)
- GIGM 0.05
- BIVI 0.13
- MACD
- GIGM 0.00
- BIVI 0.23
- Stochastic Oscillator
- GIGM 47.73
- BIVI 52.63
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.